Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R

Journal of Molecular Medicine

Volumn 92, Issue 2, 2014, Pages 177-184

  Kloster, Eugen ^a   Saft, Carsten ^b   Akkad, Denis A ^a   Epplen, Jörg T ^a   Arning, Larissa ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Age at onset; Genetic modifier; Huntington disease; NPY; NPY2R; Promoter polymorphisms

Indexed keywords

AGE OF ONSET; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COHORT STUDIES; EXONS; GENE FREQUENCY; GENOTYPE; GERMANY; HUMANS; HUNTINGTON DISEASE; MUTATION; NERVE TISSUE PROTEINS; NEUROPEPTIDE Y; PC12 CELLS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RATS; RECEPTORS, NEUROPEPTIDE Y;

EID: 84894056838     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1092-3     Document Type: Article

References (45)

1. Gusella JF, MacDonald ME (2009) Huntington's disease: the case for genetic modifiers. Genome Med 1:80
2. Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB (1988) Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A 85:5733-5737
3. Cicchetti F, Gould PV, Parent A (1996) Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease. Brain Res 730:232-237
4. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. doi: 10.1016/S1474-4422(13)70088-7
5. Dawbarn D, De Quidt ME, Emson PC (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res 340:251-260
6. Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, Martin JB (1988) Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann Neurol 23:562-569
7. Andre VM, Cepeda C, Levine MS (2010) Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 16:163-178
8. Malva JO, Xapelli S, Baptista S, Valero J, Agasse F, Ferreira R, Silva AP (2012) Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. Neuropeptides 46:299-308
9. Decressac M, Barker RA (2012) Neuropeptide Y and its role in CNS disease and repair. Exp Neurol 238:265-272
10. Sato N, Ogino Y, Mashiko S, Ando M (2009) Modulation of neuropeptide Y receptors for the treatment of obesity. Expert Opin Ther Pat 19:1401-1415
11. Stanic D, Mulder J, Watanabe M, Hokfelt T (2011) Characterization of NPY Y2 receptor protein expression in the mouse brain. II. Coexistence with NPY, the Y1 receptor, and other neurotransmitter-related molecules. J Comp Neurol 519:1219-1257
12. Chambers AP, Woods SC (2012) The role of neuropeptide Y in energy homeostasis. Handb Exp Pharmacol 209:23-45. doi: 10.1007/978-3-642-24716-3-2
13. Wiest R, Jurzik L, Herold T, Straub RH, Scholmerich J (2007) Role of NPY for vasoregulation in the splanchnic circulation during portal hypertension. Peptides 28:396-404
14. Baraban SC (2004) Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 38:261-265
15. Lee NJ, Herzog H (2009) NPY regulation of bone remodelling. Neuropeptides 43:457-463
16. Wu G, Feder A, Wegener G, Bailey C, Saxena S, Charney D, Mathe AA (2011) Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin Ther Targets 15:1317-1331
17. Fujita W, Takahashi M, Tokuyama S (2010) The mechanism of the development of drug dependence. Nihon Rinsho 68:1445-1450
18. Woldbye DP, Angehagen M, Gotzsche CR, Elbrond-Bek H, Sorensen AT, Christiansen SH, Olesen MV, Nikitidou L, Hansen TV, Kanter-Schlifke I et al (2010) Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain 133:2778-2788
19. Noe F, Frasca A, Balducci C, Carli M, Sperk G, Ferraguti F, Pitkanen A, Bland R, Fitzsimons H, During M et al (2009) Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics 6:300-306
20. Sawada M, Sawamoto K (2013) Mechanisms of neurogenesis in the normal and injured adult brain. Keio J Med 62:13-28
21. Curtis MA, Penney EB, Pearson AG, van Roon-Mom WM, Butterworth NJ, Dragunow M, Connor B, Faull RL (2003) Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci U S A 100:9023-9027
22. Curtis MA, Eriksson PS, Faull RL (2007) Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. Clin Exp Pharmacol Physiol 34:528-532
23. Decressac M, Prestoz L, Veran J, Cantereau A, Jaber M, Gaillard A (2009) Neuropeptide Y stimulates proliferation, migration and differentiation of neural precursors from the subventricular zone in adult mice. Neurobiol Dis 34:441-449
24. Gil-Mohapel J, Simpson JM, Ghilan M, Christie BR (2011) Neurogenesis in Huntington's disease: can studying adult neurogenesis lead to the development of new therapeutic strategies? Brain Res 1406:84-105
25. Decressac M, Wright B, Tyers P, Gaillard A, Barker RA (2010) Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp Neurol 226:24-32
26. Taherzadeh-Fard E, Saft C, Akkad DA, Wieczorek S, Haghikia A, Chan A, Epplen JT, Arning L (2011) PGC-1alpha downstream transcription factors NRF-1 and TFAM are genetic modifiers of Huntington disease. Mol Neurodegener 6:32. doi: 10.1186/1750-1326-6-32
27. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA et al (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78:690-695
28. Aiken CT, Tobin AJ, Schweitzer ES (2004) A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 16:546-555
29. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265
30. Shah SH, Freedman NJ, Zhang L, Crosslin DR, Stone DH, Haynes C, Johnson J, Nelson S, Wang L, Connelly JJ et al (2009) Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet 5:e1000318
31. Pesonen U (2008) NPY L7P polymorphism and metabolic diseases. Regul Pept 149:51-55
32. Zhou Z, Zhu G, Hariri AR, Enoch MA, Scott D, Sinha R, Virkkunen M, Mash DC, Lipsky RH, Hu XZ et al (2008) Genetic variation in human NPY expression affects stress response and emotion. Nature 452:997-1001
33. Domschke K, Dannlowski U, Hohoff C, Ohrmann P, Bauer J, Kugel H, Zwanzger P, Heindel W, Deckert J, Arolt V et al (2010) Neuropeptide Y (NPY) gene: Impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 20:301-309
34. Sommer WH, Lidstrom J, Sun H, Passer D, Eskay R, Parker SC, Witt SH, Zimmermann US, Nieratschker V, Rietschel M et al (2010) Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum Mutat 31:E1594-E1608
35. Itokawa M, Arai M, Kato S, Ogata Y, Furukawa A, Haga S, Ujike H, Sora I, Ikeda K, Yoshikawa T (2003) Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett 347:202-204
36. Ionescu AM, Drissi H, Schwarz EM, Kato M, Puzas JE, McCance DJ, Rosier RN, Zuscik MJ, O'Keefe RJ (2004) CREB Cooperates with BMP-stimulated Smad signaling to enhance transcription of the Smad6 promoter. J Cell Physiol 198:428-440
37. Chiang MC, Lee YC, Huang CL, Chern Y (2005) cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J Biol Chem 280:14331-14340
38. Taherzadeh-Fard E, Saft C, Wieczorek S, Epplen JT, Arning L (2010) Age at onset in Huntington's disease: replication study on the associations of ADORA2A, HAP1 and OGG1. Neurogenetics 11:435-439
39. Dhaenens CM, Burnouf S, Simonin C, Van Brussel E, Duhamel A, Defebvre L, Duru C, Vuillaume I, Cazeneuve C, Charles P et al (2009) A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol Dis 35:474-476
40. Beal MF, Swartz KJ, Finn SF, Mazurek MF, Kowall NW (1991) Neurochemical characterization of excitotoxin lesions in the cerebral cortex. J Neurosci 11:147-158
41. Mitchell IJ, Cooper AJ, Griffiths MR (1999) The selective vulnerability of striatopallidal neurons. Prog Neurobiol 59:691-719
42. Gonzales C, Lin RC, Chesselet MF (1992) Relative sparing of GABAergic interneurons in the striatum of gerbils with ischemia-induced lesions. Neurosci Lett 135:53-58
43. DiMaggio DA, Farah JM Jr, Westfall TC (1994) Effects of differentiation on neuropeptide-Y receptors and responses in rat pheochromocytoma cells. Endocrinology 134:719-727
44. Lu C, Everhart L, Tilan J, Kuo L, Sun CC, Munivenkatappa RB, Jonsson-Rylander AC, Sun J, Kuan-Celarier A, Li L et al (2010) Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy. Oncogene 29:5630-5642
45. Benarroch EE (2009) Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology 72:1016-1020